DISEASE INDICATIONS: Breast Cancer, Gynaecological Cancer
MANUFACTURER: AstraZeneca AB
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Therapeutic Goods Administration (TGA)
Lynparza is an oral medication used to treat some types of cancer by blocking the action of the PARP enzyme, preventing cancer cells from multiplying. It is used for ovarian, breast, and pancreatic cancer patients with a BRCA gene mutation or triple-negative breast cancer.